Business Wire - Thursday, May 20, 1999
The proposed legislation mirrors the 1998 California law requiring that hospitals use needles designed with `engineered controls' to protect the workers from accidental needlesticks. "Mandating the use of safe needles on a national level will have a tremendous impact in preventing accidental needlesticks," said Tom Sutton, Executive Vice President at Bio-Plexus, Inc. According to Congressman Stark's office, needlestick injuries caused by hollow-bore needles account for 86% of all reported occupational HIV exposures, and every year more than 200 health care workers die of occupationally acquired hepatitis.
"If safety needles are nationally mandated, as it appears they may be, conventional, `unsafe' needles will become obsolete," Sutton concluded. In addition to being endorsed by Bio-Plexus, the act is also supported by organizations including: the American Nurses Association, Kaiser Permanente, the American Federation of State, County and Municipal Employees, the Service Employees International Union, the American Federation of Teachers, and Becton Dickinson, a major medical device manufacturer.
On the state level, legislation mandating the use of safety needles has passed in California and Tennessee. In April, Maryland passed a bill requiring the state to develop recommendations to protect health care workers. Legislation is pending in Texas, New Jersey, Arkansas, Connecticut, Massachusetts, Michigan, and New York.
Bio-Plexus, Inc. (NASDAQ:BPLX), designs, develops, manufactures, markets, and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD(R) and DROP-IT(R) brand names. In a Centers for Disease Control study, Punctur-Guard Blood Collection Needles were found to reduce the rate of accidental needlesticks among healthcare workers by 76%, the highest rate of any device studied. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis.
NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS WHICH ARE SUBJECT TO RISKS AND UNCERTAINTIES. THE ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE DESCRIBED IN ANY SUCH FORWARD-LOOKING STATEMENT AS A RESULT OF FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE COMPANY.
--30--mb/bos*
CONTACT: Bio-Plexus, Inc. Carol Coburn 860.870.6112, extension 317 BIO.PLEXUS@SNET.NET
990520
BW990508
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .